Evidence is mounting that new therapies already used to treat gut diseases, type 2 diabetes, and obesity may help people with alcohol use disorder (AUD).

Researchers explore the therapeutic potential and clinical insights of GP1-RAs in the management of metabolic ...

Altimmune is redefining success in both obesity and MASH to position Pemvidutide in blue ocean categories. Read why I rate ...

The secret agent in the decrease might be semaglutide, a GLP-1 receptor agonist that fuels popular weight loss drugs like ...

A new study reveals a slight drop in U.S. obesity rates, driven by weight loss drugs, lifestyle changes post-COVID, and ...

FTC approves Novo Holdings' $16.5B Catalent acquisition. Deal includes selling 3 facilities to Novo Nordisk for $11B, despite ...

New research shows how weight loss meds like Wegovy are reshaping alcohol habits, offering new insights into addiction ...

Eli Lilly (LLY 0.86%) and Novo Nordisk (NVO -1.53%) have competed for decades. They're both leaders in the areas of insulin ...

Wall Street analysts who follow Viking and Summit expect further gains in 2025. Quick gains are often lost on Wall Street, ...

In this context, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a potential game-changer. Initially ...

Recent studies show medications like Ozempic, originally designed for type 2 diabetes and weight loss, may help people ...

Lawmakers are considering some small health policy provisions in an end-of-year package – but experts don’t expect anything major.